<DrugInformationSummary id="CDR0000809050"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about pacritinib citrate
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/pacritinib-citrate">Pacritinib Citrate</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000609888">pacritinib citrate</TerminologyLink><GlossaryLink ref="CDR0000808599">pacritinib citrate</GlossaryLink><USBrandNames><USBrandName>Vonjo</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>pak-RIH-tih-nib SIH-trayt</TermPronunciation><MediaLink ref="CDR0000809824" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000809825" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5ab444-0e1a-4984-99db-76ad11a298ee&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Pacritinib Citrate</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5ab444-0e1a-4984-99db-76ad11a298ee&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_8"><Title>Use in Cancer</Title>                                                              
  <Para id="_9">Pacritinib citrate
         is approved to treat adults with:</Para>                          
  <ItemizedList Style="bullet" id="_7">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045947" dictionary="Cancer.gov" audience="Patient">Myelofibrosis</GlossaryTermRef></Strong> (a <GlossaryTermRef href="CDR0000045622" dictionary="Cancer.gov" audience="Patient">bone marrow</GlossaryTermRef> disease) that is intermediate or high risk with a very low platelet count, including the following types:<ItemizedList Style="bullet" id="_4"><ListItem><GlossaryTermRef href="CDR0000306488" dictionary="Cancer.gov" audience="Patient">Primary myelofibrosis</GlossaryTermRef>.</ListItem><ListItem>Post-<GlossaryTermRef href="CDR0000426418" dictionary="Cancer.gov" audience="Patient">polycythemia vera</GlossaryTermRef> myelofibrosis.</ListItem><ListItem>Post-<GlossaryTermRef href="CDR0000256562" dictionary="Cancer.gov" audience="Patient">essential thrombocythemia</GlossaryTermRef> myelofibrosis.</ListItem></ItemizedList></ListItem></ItemizedList>
  <Para id="_10">Pacritinib citrate is approved under FDAâ€™s Accelerated Approval Program. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that it provides a clinical benefit in these patients.</Para><Para id="_11">Pacritinib citrate
         is also being studied in the treatment of other conditions.</Para>
 </Section><Section id="_About"><Title>More About Pacritinib Citrate</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/609888">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.17">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a622043.html">Pacritinib Citrate</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.18"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.19">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C185891">Find Clinical Trials for Pacritinib Citrate</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2022-03-23</DateFirstPublished><DateLastModified>2022-06-24</DateLastModified></DrugInformationSummary>
